Literature DB >> 9510480

Responses of total and quiescent cell populations in solid tumors to boron and gadolinium neutron capture reaction using neutrons with two different energy spectra.

S Masunaga1, K Ono, Y Sakurai, M Suzuki, M Takagaki, T Kobayashi, Y Kinashi, M Akaboshi.   

Abstract

In neutron capture therapy, whose effectiveness depends on the tumor distribution of neutron capture compound and the neutron energy distribution, controlling quiescent tumor cells with clonogenic potential is critical for therapeutic gain, as is the case in conventional radio- and chemotherapy. Tumor-bearing mice were continuously given 5-bromo-2'-deoxyuridine (BrdU) to label all proliferating cells. After administration of sodium borocaptate-10B (BSH), dl-p-boronophenylalanine-10B (BPA) or gadodiamide hydrate (Omniscan), the tumors were irradiated with neutrons of different cadmium (Cd) ratio, and then isolated and incubated with cytochalasin-B (a cytokinesis blocker). The micronucleus (MN) frequency in cells without BrdU labeling (quiescent cells) was determined using immunofluorescence staining for BrdU, and that for total cells was obtained from tumors not pretreated with BrdU. Without drugs, quiescent cells showed lower MN frequencies than total cells, but neutron irradiation reduced gamma-ray sensitivity difference between the two. Relative biological effectiveness (RBE) of neutrons compared with gamma-rays was greater in quiescent cells than in total cells, and low Cd ratio neutrons tended to exhibit large RBE values. With neutron capture compounds, MN frequency for each cell population was increased, especially when high Cd ratio neutrons were used. BPA increased the MN frequency for total cells to a greater extent than BSH. However, the sensitivity of quiescent cells treated with BPA was lower than that in BSH-treated quiescent cells. This tendency was clearly observed in high Cd ratio neutrons. Omniscan only slightly increased the MN frequency in both cell populations, compared with irradiation alone, without drugs. From the viewpoint of increasing the quiescent cell sensitivity, tumors should be irradiated with high Cd ratio neutrons after BSH administration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9510480      PMCID: PMC5921587          DOI: 10.1111/j.1349-7006.1998.tb00483.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  18 in total

1.  Radiation effect of gadolinium-neutron capture reactions on the survival of Chinese hamster cells.

Authors:  Y Akine; N Tokita; T Matsumoto; H Oyama; S Egawa; O Aizawa
Journal:  Strahlenther Onkol       Date:  1990-12       Impact factor: 3.621

2.  An overview: radiation sources, beam quality, dosimetry and spectroscopy in neutron capture therapy.

Authors:  K Kanda
Journal:  Strahlenther Onkol       Date:  1989 Feb-Mar       Impact factor: 3.621

3.  Production of chromosome aberrations, micronuclei, and sister-chromatid exchanges by 24-keV epithermal neutrons in human G0 lymphocytes.

Authors:  S Z Aghamohammadi; D T Goodhead; J R Savage
Journal:  Mutat Res       Date:  1989-04       Impact factor: 2.433

4.  Differing sensitivity to fluorescent light in Chinese hamster cells containing equally incorporated quantities of BUdR versus IUdR.

Authors:  J B Mitchell; G Morstyn; A Russo; T J Kinsella; A Fornace; S McPherson; E Glatstein
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-08       Impact factor: 7.038

Review 5.  Boron neutron capture therapy of brain tumors: past history, current status, and future potential.

Authors:  R F Barth; A H Soloway; R M Brugger
Journal:  Cancer Invest       Date:  1996       Impact factor: 2.176

Review 6.  Prospects for the application of fast neutrons in cancer therapy. Radiobiological bases and survey of the clinical data.

Authors:  A Wambersie; D K Bewley; C M Lalanne
Journal:  Bull Cancer       Date:  1986       Impact factor: 1.276

7.  The response of quiescent cell populations in murine solid tumors to irradiation with fast neutrons.

Authors:  S Masunaga; K Ono; K Akuta; M Akaboshi; M Abe; K Ando; S Koike
Journal:  Acta Oncol       Date:  1994       Impact factor: 4.089

8.  Design and preparation of ethyl cellulose microcapsules of gadopentetate dimeglumine for neutron-capture therapy using the Wurster process.

Authors:  Y Fukumori; H Ichikawa; H Tokumitsu; M Miyamoto; K Jono; R Kanamori; Y Akine; N Tokita
Journal:  Chem Pharm Bull (Tokyo)       Date:  1993-06       Impact factor: 1.645

9.  Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy.

Authors:  K Ono; S I Masunaga; Y Kinashi; M Takagaki; M Akaboshi; T Kobayashi; K Akuta
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-03-15       Impact factor: 7.038

Review 10.  Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer.

Authors:  S R Denmeade; X S Lin; J T Isaacs
Journal:  Prostate       Date:  1996-04       Impact factor: 4.104

View more
  3 in total

Review 1.  A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond.

Authors:  Yoshitaka Matsumoto; Nobuyoshi Fukumitsu; Hitoshi Ishikawa; Kei Nakai; Hideyuki Sakurai
Journal:  J Pers Med       Date:  2021-08-23

2.  Evaluation of the potential of p-boronophenylalaninol as a boron carrier in boron neutron capture therapy, referring to the effect on intratumor quiescent cells.

Authors:  S I Masunaga; K Ono; M Kirihata; M Takagaki; Y Sakurai; Y Kinashi; T Kobayashi; H Nagasawa; Y Uto; H Hori
Journal:  Jpn J Cancer Res       Date:  2001-09

3.  An attempt to improve the therapeutic effect of boron neutron capture therapy using commonly employed 10B-carriers based on analytical studies on the correlation among quiescent tumor cell characteristics, tumor heterogeneity and cancer stemness.

Authors:  Shin-Ichiro Masunaga; Yu Sanada; Keizo Tano; Yoshinori Sakurai; Hiroki Tanaka; Takushi Takata; Minoru Suzuki; Koji Ono
Journal:  J Radiat Res       Date:  2020-11-16       Impact factor: 2.724

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.